Clinical Data

TVAX Immunotherapy has been evaluated in Phase 1/2 clinical trials in 43 patients with recurrent grade 3 and grade 4 gliomas who have previously failed surgery, radiotherapy and chemotherapy.  Results of these studies have demonstrated significantly increased median survival for patients treated with TVAX Immunotherapy as compared to historical controls (see Kaplan-Meier survival curves below). 

Additionally, a significant number of these patients’ cancers underwent objective clinical responses.  Importantly, treatment with TVAX Immunotherapy resulted in only minimal adverse effects including fever, chills, headache and nausea.